TNFerade, an adenovector carrying the transgene for human tumor necrosis factor α, for patients with advanced solid tumors: Surgical experience and long-term follow-up

Annals of Surgical Oncology

Volumn 12, Issue 10, 2005, Pages 825-830

  McLoughlin, James M ^a   McCarty, Todd M ^a   Cunningham, Casey ^b   Clark, Valerie ^b   Senzer, Neil ^b   Nemunaitis, John ^b   Kuhn, Joseph A ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Mary Crowley Medical Research Center   (United States)

Author keywords

Adenovirus; Phase I; TNFerade; Tumor necrosis factor

Indexed keywords

ADENOVIRUS VECTOR; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TNFERADE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOTENSION; INJECTION SITE REACTION; IONIZING RADIATION; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; PROMOTER REGION; PROTEIN SECRETION; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TRANSGENE; TUMOR REGRESSION; ULCER; VOMITING;

ADENOVIRIDAE; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROMOTER REGIONS (GENETICS); TRANSGENES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 25144471132     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2005.03.023     Document Type: Article

References (42)

1. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-70.
2. Feinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988;6:1328-34.
3. Mannel DN, Moore RN, Mergenhagen SE. Macrophages as a source of tumoricidal activity (tumor-necrotizing factor). Infect Immun 1980;30:523-30.
4. Larrick JW, Wright SC. Cytotoxic mechanism of tumor necrosis factor-alpha. FASEB J 1990;4:3215-23.
5. Asher A, Mule JJ, Reichert CM, et al. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-74.
6. Tcherkasowa AE, Adam-Klages S, Kruse ML, et al. Interaction with factor associated with neutral sphingomyelinase activation, a WD motif-containing protein, identifies receptor for activated C-kinase 1 as a novel component of the signaling pathways of the p55 TNF receptor. J Immunol 2002;169:5161-70.
7. Wallach D, Varfolomeev EE, Malinin NL, et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Ann Rev Immunol 1999;17:331-67.
8. Schwandner R, Wiegmann K, Bernardo K, et al. TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase. J Biol Chem 1998;273: 5916-22.
9. Kulik G, Carson JP, Vomastek T, et al. Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells. Cancer Res 2001;61:2713-9.
10. Kimura K, Gelmann EP. Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. J Biol Chem 2000;275:8610-7.
11. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-7.
12. Villa P, Kaufmann SH, Earnshaw WC. Caspases and caspase inhibitors. Trends Biochem Sci 1997;22:388-93.
13. Dbaibo GS, Perry DK, Gamard CJ, et al. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-alpha: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J Exp Med 1997;185:481-90.
14. Wiegmann K, Schutze S, Machleidt T, et al. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 1994;78:1005-15.
15. Green DR. Apoptosis. Death deceiver (comment). Nature 1998;396:629-30.
16. Mauceri HJ, Hanna NN, Wayne JD, et al. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 1996;56:4311-4.
17. Mahadevan V, Malik ST, Meager A, et al. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 1990;50:5537-42.
18. Fukumura D, Salehi HA, Witwer B, et al. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res 1995;55:4824-9.
19. Balkwill FR, Lee A, Aldam G, et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 1986;46:3990-3.
20. Korpelainen EI, Gamble JR, Smith WB, et al. The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor alpha and potentiates interleukin 8 secretion and neutrophil transmigration. Proc Natl Acad Sci U S A 1993;90:11137-41.
21. Pilaro AM, Taub DD, McCormick KL, et al. TNF-alpha is a principal cytokine involved in the recruitment of NK cells to liver parenchyma. J Immunol 1994;153:333-42.
22. Seung LP, Mauceri HJ, Beckett MA, et al. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res 1995;55:5561-5.
23. Hallahan DE, Spriggs DR, Beckett MA, et al. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A 1989;86:10104-7.
24. Sugarman BJ, Aggarwal BB, Hass PE, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985;230:943-5.
25. Fransen L, Van der Heyden J, Ruysschaert R, Fiers W. Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 1986;22:419-26.
26. Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987;5:1942-51.
27. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988;80:1039-44.
28. Hieber U, Heim ME. Tumor necrosis factor for the treatment of malignancies. Oncology 1994;51:142-53.
29. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
30. Thom AK, Alexander HR, Andrich MP, et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 1995;13:264-73.
31. Fraker D, Alexander H, Pass H. Biologic therapy with TNF systemic and regional administration. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer, Fourth Edition. Philadelphia: Lippincott, 1994:62-9.
32. Marr RA, Hitt M, Muller WJ, et al. Tumour therapy in mice using adenovirus vectors expressing human TNFa. Int J Oncol 1998;12:509-15.
33. Rasmussen H, Rasmussen C, Lempicki M, et al. TNFerade biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002; 9:951-7.
34. Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004;22:592-601.
35. Mundt AJ, Vijayakumar S, Nemunaitis J, et al. A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 2004;10:5747-53.
36. Datta R, Rubin E, Sukhatme V, et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci U S A 1992;89:10149-53.
37. Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist 2002;7:46-59.
38. Brough DE, Lizonova A, Hsu C, et al. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996;70:6497-501.
39. Creaven PJ, Plager JE, Dupere S, et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987;20:137-44.
40. Talmadge JE, Phillips H, Schneider M, et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988;48:544-50.
41. Johnson JP. The role of ICAM-1 in tumor development. Chem Immunol 1991;50:143-63.
42. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988;141:2629-34.